Drug-induced impotence.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects; D002090:Butyrophenones / Q000009:adverse effects; D003000:Clonidine / Q000009:adverse effects; D007172:Erectile Dysfunction / Q000139:chemically induced*; D004967:Estrogens / Q000009:adverse effects; D000431:Ethanol / Q000009:adverse effects; D005730:Ganglionic Blockers / Q000009:adverse effects; D006145:Guanethidine / Q000009:adverse effects; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects; D009294:Narcotics / Q000009:adverse effects; D010276:Parasympatholytics / Q000009:adverse effects; D010640:Phenothiazines / Q000009:adverse effects; D010643:Phenoxybenzamine / Q000009:adverse effects; D046948:Secologanin Tryptamine Alkaloids / Q000009:adverse effects; D013892:Thioxanthenes / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D000929:Antidepressive Agents, Tricyclic; D000959:Antihypertensive Agents; D002090:Butyrophenones; D004967:Estrogens; D005730:Ganglionic Blockers; D008996:Monoamine Oxidase Inhibitors; D009294:Narcotics; D010276:Parasympatholytics; D010640:Phenothiazines; D046948:Secologanin Tryptamine Alkaloids; D013892:Thioxanthenes; D010643:Phenoxybenzamine; D001569:Benzodiazepines; D000431:Ethanol; D008750:Methyldopa; D003000:Clonidine; D006145:Guanethidine